GLP-1 agonists strip fat fast, but they don't discriminate, lean tissue goes with it. Competitors using semaglutide or tirzepatide have turned to IGF-1 LR3 as a muscle-sparing countermeasure, hoping the peptide's anabolic signaling can offset the catabolic tilt of rapid weight loss.
This article discusses peptides as research compounds. It is not medical advice.
Why IGF-1 LR3 Appears in GLP-1 Stacks
GLP-1 receptor agonists reduce appetite and slow gastric emptying, which drives calorie deficits large enough to pull muscle protein into the furnace. One competitor mentioned running tirzepatide at 10 mg weekly and watching his squat drop 15 kg over eight weeks despite keeping volume constant. The weight came off, but so did strength.
IGF-1 LR3 is a synthetic analog of insulin-like growth factor 1, engineered with an N-terminal extension and an arginine substitution at position 3. Those modifications extend its half-life to roughly 20–30 hours and reduce binding to IGF-binding proteins, leaving more free peptide in circulation. In rodent models, exogenous IGF-1 LR3 increased skeletal muscle protein synthesis and attenuated atrophy during calorie restriction (PubMed).
The logic: if GLP-1 drugs create a net catabolic environment through energy deficit, IGF-1 LR3 might tilt the balance back toward anabolism by activating the PI3K/Akt/mTOR pathway in muscle tissue. Or maybe not, human data remain sparse, and most of what circulates in lifting forums comes from self-experimentation rather than controlled trials.
IGF-1 LR3 Profile and Mechanism
IGF-1 LR3 binds to the IGF-1 receptor on muscle cells, triggering downstream signaling cascades that promote glucose uptake, amino acid incorporation, and ribosomal protein translation. Unlike endogenous IGF-1, the LR3 variant stays active longer and diffuses more readily into tissue because it sidesteps the binding proteins that normally sequester the native hormone.
Key characteristics reported in the literature include:
- Half-life of 20–30 hours, compared to minutes for native IGF-1
- Reduced affinity for IGF-binding proteins, increasing bioavailability
- Potent activation of muscle protein synthesis pathways in vitro and in animal models
- Potential for localized hypertrophy when administered via intramuscular injection
Researchers have used IGF-1 LR3 in cell culture to study myoblast proliferation and differentiation. In one study, treating C2C12 myoblasts with IGF-1 LR3 at 100 ng/mL increased myotube diameter and upregulated markers of muscle differentiation (PubMed). Whether those effects translate to intact human muscle under calorie restriction is less clear.
Dosing Protocols Seen in Research and Community Reports
Published human trials using IGF-1 LR3 are scarce. Most dosing information comes from animal studies, cell work, and anecdotal logs posted in peptide forums. Competitors stacking it with GLP-1 drugs typically report subcutaneous or intramuscular injections in the range of 20–80 mcg per day, often split into bilateral injections when targeting specific muscle groups.
One frequently cited protocol:
- 20–40 mcg per day, administered subcutaneously in the morning
- Run for 4–6 weeks, then pause for an equal duration to allow receptor sensitivity to recover
- Some users front-load at 60–80 mcg for the first week, then taper to maintenance
A competitor running semaglutide at 1 mg weekly reported dosing IGF-1 LR3 at 30 mcg daily for five weeks. He noted stable lean mass on DEXA despite a 4 kg total weight drop, though training volume and protein intake remained high throughout. Another lifter mentioned bilateral intramuscular injections of 40 mcg into quads and delts, hoping for site-specific hypertrophy, but saw no measurable asymmetry on follow-up scans.
Researchers conducting independent work should follow institutional protocols and ethics review where applicable.
Timeline and Monitoring Considerations
IGF-1 LR3's extended half-life means steady-state plasma levels accumulate over the first few days. Competitors typically assess response at the two-week mark, using strength benchmarks and weekly weigh-ins to gauge whether lean mass is holding. DEXA or bioimpedance scans at weeks 0, 4, and 8 offer more granular data, though access varies.
Because GLP-1 drugs suppress appetite, protein intake often drops inadvertently. One poster on a peptide forum noted that his semaglutide-induced nausea cut daily protein from 200 g to 120 g, and even with IGF-1 LR3 at 40 mcg daily, his lean mass declined. Raising protein back to 1.8 g/kg stabilized the loss, suggesting the peptide alone couldn't overcome a severe deficit in substrate availability.
Bloodwork considerations include:
- Fasting glucose and HbA1c, since IGF-1 can enhance insulin sensitivity and occasionally trigger hypoglycemia
- Serum IGF-1 levels, though exogenous LR3 may not register on standard assays designed for endogenous IGF-1
- Liver enzymes, as high-dose IGF-1 analogs have been associated with transient ALT elevation in animal models
Competitors often run IGF-1 LR3 for four to six weeks, then cycle off for an equal period. The rationale is receptor downregulation, though direct evidence for this timeline in humans is absent. Some stack it with Tesamorelin for preserving lean muscle during GLP-1 weight loss, hoping that upstream growth hormone release will amplify endogenous IGF-1 production and create a synergistic anabolic environment.
Comparative Context: Other Peptides in the Muscle-Sparing Stack
IGF-1 LR3 isn't the only peptide competitors layer onto GLP-1 protocols. Tesamorelin, a growth-hormone-releasing hormone analog, has been studied in HIV-associated lipodystrophy and shown to reduce visceral fat while preserving lean mass (PubMed). Dosing typically runs 2 mg subcutaneously per day, and some lifters prefer it over IGF-1 LR3 because it works through endogenous pathways rather than flooding receptors with a synthetic analog.
MK-677, a ghrelin mimetic, stimulates growth hormone and IGF-1 release but also increases appetite, a double-edged effect when paired with a GLP-1 drug designed to suppress it. Ipamorelin and CJC-1295 are growth-hormone secretagogues with shorter half-lives, often dosed together in the evening to mimic pulsatile GH release. BPC-157, though primarily studied for tendon and gut repair, appears in some logs as a recovery adjunct, though its relevance to lean-mass preservation is speculative.
Except, and this matters, none of these peptides have been tested head-to-head in a controlled trial against muscle loss during GLP-1 treatment. The evidence base is a patchwork of rodent studies, in vitro work, and self-reported logs. One competitor summed it up: "We're all running our own n=1 trials and hoping the next DEXA doesn't show we guessed wrong."
What the Literature Does and Doesn't Say
A 2010 study in rats subjected to calorie restriction found that IGF-1 administration preserved gastrocnemius muscle mass compared to saline controls (PubMed). The treated group maintained higher myofibrillar protein content and showed less activation of the ubiquitin-proteasome pathway, a marker of muscle breakdown. But the dose used, 1 mg/kg body weight, scales poorly to human protocols, and the study didn't model the pharmacology of a GLP-1 agonist.
Human trials of recombinant IGF-1 (not the LR3 analog) in elderly populations have shown modest increases in lean mass, though gains were smaller than those seen with resistance training alone (PubMed). IGF-1 LR3 has not been the subject of large-scale human trials for muscle preservation, and its legal status as a research chemical means most use occurs outside clinical oversight.
Posters in peptide forums occasionally reference unpublished data or cite "studies" that don't appear in PubMed. One thread claimed IGF-1 LR3 at 50 mcg daily prevented all lean-mass loss during a 12-week semaglutide run, but no citation was provided and the original poster later deleted the account. Verification remains a persistent problem in this corner of the internet.
Practical Observations from the Lifting Community
Competitors who log their IGF-1 LR3 use alongside GLP-1 drugs report mixed outcomes. Some note stable or slightly increased lean mass on DEXA, often attributing the result to high protein intake and continued heavy training rather than the peptide alone. Others see no measurable difference compared to GLP-1 monotherapy, and a few report transient joint pain or water retention that resolved after stopping the peptide.
One lifter mentioned running IGF-1 LR3 at 40 mcg daily for six weeks while on tirzepatide 7.5 mg weekly. His total weight dropped 6 kg, DEXA showed a 1 kg loss of lean mass, and his squat max fell 10 kg. He concluded the peptide "maybe blunted the damage, maybe did nothing," and switched to a Tesamorelin stack for his next cut.
Another competitor dosed 60 mcg daily, split into two 30 mcg injections, and reported no change in lean mass over eight weeks on semaglutide 1 mg. His protein intake averaged 2.2 g/kg, and he maintained four training sessions per week. He attributed the preservation to training and diet, calling the peptide "insurance I can't prove I needed."
And some users report side effects: mild hypoglycemia an hour post-injection, localized site swelling, and occasional headaches. One poster noted persistent fatigue that resolved when he dropped the dose from 80 mcg to 40 mcg daily.
Where the Evidence Is Stronger
If the goal is muscle preservation during GLP-1 treatment, the strongest evidence supports high protein intake (≥1.6 g/kg) and resistance training at least three times per week. A 2021 meta-analysis found that protein supplementation during calorie restriction reduced lean-mass loss by an average of 0.6 kg compared to lower-protein controls (PubMed). No peptide intervention has demonstrated a larger effect in humans.
Tesamorelin has more published human data than IGF-1 LR3, particularly in the context of visceral fat reduction and lean-mass preservation. Competitors looking for a peptide adjunct often weigh Tesamorelin's regulatory history and clinical trial record against IGF-1 LR3's theoretical potency and shorter half-life.
But the reality is that most lifters stacking peptides with GLP-1 drugs are operating in a zone where published evidence thins out fast. The protocols are borrowed from bodybuilding forums, adjusted by trial and error, and documented in logs that rarely make it into peer review. One competitor put it plainly: "We're writing the playbook as we go, and half the pages are blank."